AVITA Medical Inc（RCEL）财务数据RCELAVITA Medical Inc

Evaluating the bottom line, AVITA Medical Inc maintains a gross margin of 82.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -31.29%, while the net margin is -35.31%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RCEL converts its operational activities into shareholder value.

In the context of the broader market, RCEL competes directly with industry leaders such as SMTI and OBIO. With a market capitalization of $242.78M, it holds a significant position in the sector. When comparing efficiency, RCEL's gross margin of 82.17% stands against SMTI's 90.76% and OBIO's 71.59%. Such benchmarking helps identify whether AVITA Medical Inc is trading at a premium or discount relative to its financial performance.

AVITA Medical reported revenue of $21.7 million in Q2 2026, a 10% sequential increase, and a net loss of $7.66 million, which is an improvement from previous quarters. The gross margin remains strong at 82.17%.